Lung Cancer Archives - Page 3 of 144 - Cancer Therapy Advisor

KRAS was neither prognostic nor predictive of benefit for either docetaxel or erlotinib in NSCLC.

SITC 2020

PD-L1 Expression in Extracellular Vesicles as a Predictive Biomarker

By

November 13, 2020

Extracellular vesicles carrying PD-L1 as cargo may function as a predictive biomarker for immunotherapy response in NSCLC.

The MET alteration occurs in 3% to 4% of patients with the condition.

Lung Cancer

Adjuvant Osimertinib: A New Standard in EGFR-Mutant NSCLC

By

Leah Lawrence

November 13, 2020

At 2 years, twice as many patients with stage II to IIIA disease in the osimertinib group were alive and disease-free as in the placebo group.

Infections often precede a formal diagnosis of CLL. Researchers found that antimicrobial use began to rise 6 years prior to CLL diagnosis.

Lung Cancer

Efficacy of ALK TKIs According to ALK Tumor Status

By

Susan Moench, PhD, PA-C

November 12, 2020

This analysis compared the efficacy outcomes of subgroups of patients with NSCLC treated with alectinib vs crizotinib according to ALK tumor status.

Sometimes the distinctions between cancer treatment groups are a little blurry. Here’s a guide to their definitions and origins.

General Oncology

Targeted Therapies, Immunotherapies, Immunomodulators: A Quick Guide to Cancer Therapy Descriptions

By

Katarina Zimmer, MSci, MS

November 12, 2020

Sometimes the distinctions between cancer treatment groups are a little blurry. Here’s a guide to their definitions and origins.

A Penn Medicine team debuts its program focused on cancer care at home — just in time for COVID-19.

SITC 2020

More NSCLC Downstaging With Neoadjuvant Chemotherapy Plus ICI

By

Andrea S. Blevins Primeau, PhD, MBA

November 12, 2020

Neoadjuvant treatment with chemotherapy plus nivolumab resulted in a greater frequency of NSCLC downstaging compared with chemotherapy or ICI treatment alone.

This frontal view x-ray of the chest shows advanced stage non-small cell lung cancer (NSCLC) of a 50-year-old woman with a long history of smoking and emphysema. The orange area depicts collapsed lung tissue at the base of the right lung, and the yellow area highlights a pleura-based density along the right hemithorax.

SITC 2020

AXL Inhibitor Plus Pembrolizumab Shows Activity in Previously Treated NSCLC

By

Andrea S. Blevins Primeau, PhD, MBA

November 11, 2020

Bemcentinib, an AXL inhibitor, was tolerable and demonstrated antitumor activity in combination with pembrolizumab in AXL-positive, relapsed NSCLC.

Lung Cancer

Telemedicine and Quality of Life in Patients With Lung Cancer

By

Steve Fiorillo

November 10, 2020

Telemedicine has become more crucial than ever in the continuing wake of the COVID-19 pandemic. Research from the US Centers for Disease Control and Prevention (CDC) showed that there was a 50% increase utilization of telehealth services in the first quarter of 2020 compared with 2019, and a 154% increase in week 13 of 2020…

Lung Cancer

Characteristics of Pediatric Mesothelioma

By

Andrea S. Blevins Primeau, PhD, MBA

November 6, 2020

Pediatric mesothelioma demonstrated distinct characteristics from adult disease, including good prognosis.

Overall, it is estimated that approximately 7% to 11% of patients experience tumor shrinkage in phase 1 trials.

General Oncology

Statistical Index Suggests That Many ICI Trials Show Uncertain Clinical Benefit

By

Andrea S. Blevins Primeau, PhD, MBA

November 5, 2020

The survival-inferred fragility index of phase 3 trials for immune checkpoint inhibitors suggests that, despite statistical significance, survival data do not show a robust clinical benefit.

Interferon or high-dose interleukin-2 were the only available options for the treatment of metastati

Lung Cancer

FoundationOne Liquid CDx Approval Expanded to PIK3CA, BRCA, and ALK Alterations

By

Andrea S. Blevins Primeau, PhD, MBA

November 3, 2020

The FDA approved FoundationOne CDx as a companion diagnostic for treatment selection of alpelisib for breast cancer, rucaparib for some gynecologic cancers, and alectinib for lung cancer.